Eplerenone

Introduction Overview

Generic Name

eplerenone

Brand Name

Inspra

Dosage Form

oral tablet (25 mg; 50 mg)

Drug Class

Aldosterone receptor antagonists, Potassium-sparing diuretics

Pharmacokinetics

Absorption:
Eplerenone is rapidly and well absorbed following oral administration, with peak plasma concentrations typically attained within one to two hours. The bioavailability of eplerenone is approximately 69%, which is favorable for oral dosing. Its absorption is not significantly influenced by food intake, allowing flexibility in dosing with or without meals. Factors such as gastrointestinal pH and motility have minimal impact on its absorption. Clinical studies have demonstrated a consistent absorption profile with reduced inter-patient variability, making dosing predictable in diverse populations.

Distribution:
Once absorbed, eplerenone exhibits moderate plasma protein binding, approximately 50-60%, primarily to albumin. It distributes extensively into tissues, including the heart and kidneys, which are major target organs for its pharmacologic action. The volume of distribution is moderate, indicative of substantial distribution beyond the vascular compartment. Eplerenone does not significantly cross the blood-brain barrier, limiting central nervous system exposure. Distribution kinetics contribute to its effectiveness in modulating aldosterone receptors in cardiovascular and renal tissues.

Metabolism:
Eplerenone undergoes extensive hepatic metabolism primarily by the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is metabolized into inactive metabolites; only a small fraction of unchanged drug is present in plasma. The CYP3A4-dependent metabolism implies that co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) can significantly increase drug plasma concentrations, raising the risk of adverse effects like hyperkalemia. Genetic polymorphisms of CYP3A4 have limited impact on metabolism due to multiple oxidative pathways.

Elimination:
The elimination half-life of eplerenone ranges from approximately 4 to 6 hours, permitting once or twice daily dosing schedules depending on clinical indication. It is primarily eliminated via hepatic metabolism, followed by renal and fecal excretion of metabolites. Less than 5% of the parent drug is excreted unchanged in urine. Renal impairment can affect drug clearance moderately; severe renal dysfunction is a contraindication due to increased risk of hyperkalemia. Hepatic impairment also influences elimination, necessitating caution in patients with liver disease. Overall, elimination kinetics support effective plasma level management through routine dosing adjustments.

Dosage Forms

Available Dosage Forms:
Eplerenone is available as oral tablets in the following strengths:
- 25 mg
- 50 mg

The tablets are formulated for once or twice daily oral administration and are intended for systemic absorption via the gastrointestinal tract.

Dosages for Adults and Adolescents:
- Congestive Heart Failure (post-myocardial infarction with reduced ejection fraction ≤40%): Initial dose is 25 mg orally once daily, with titration to a target dose of 50 mg once daily within four weeks as tolerated.
- Hypertension: Initial dose is 50 mg orally once daily; maintenance dosing is 50 mg once or twice daily depending on blood pressure response. Maximum dose recommended is 100 mg/day.
- Therapy onset is gradual, with full therapeutic effect generally observed within four weeks.

Specific Patient Populations:
- In patients with renal impairment or elevated baseline potassium, careful dose titration and monitoring are required due to increased risk of hyperkalemia.
- Dose adjustments may be necessary in hepatic impairment; however, eplerenone is generally avoided in severe liver dysfunction.
- Elderly patients may require individualized dosing considering comorbidities and concomitant medications.
- The drug has not been established for use in pediatric populations; safety and efficacy data are limited.
- No dosage modification is necessary regarding food intake, providing dosing flexibility.

Mechanism Of Action

Eplerenone is a selective aldosterone receptor antagonist, primarily targeting the mineralocorticoid receptor (MR) in the distal convoluted tubule and collecting ducts of the nephron. By competitively binding to MR, eplerenone inhibits aldosterone-induced transcriptional activities that promote sodium and water retention, potassium excretion, and myocardial fibrosis. Its high selectivity distinguishes it from other steroidal MR antagonists like spironolactone, minimizing off-target effects such as anti-androgenic activity.

At the molecular level, eplerenone blocks aldosterone binding, preventing nuclear translocation and subsequent upregulation of genes encoding sodium channels and Na+/K+-ATPase pumps. This results in enhanced natriuresis, diuresis, and potassium retention, which contribute to reduction of blood volume and blood pressure. Additionally, by antagonizing aldosterone in cardiac tissues, it mitigates pathological remodeling including fibrosis and hypertrophy, which are critical processes in heart failure progression.

Clinical implications of this mechanism include improved survival in patients with heart failure post-myocardial infarction by decreasing cardiac workload and remodeling, and effective lowering of blood pressure by reducing volume overload. Compared to spironolactone, eplerenone has a lower incidence of gynecomastia and endocrine-related side effects due to its selective receptor affinity.

Research studies have demonstrated the efficacy of eplerenone in large-scale clinical trials (e.g., EPHESUS trial), confirming its benefit in reducing mortality and hospitalization rates post-MI and in hypertension management. Ongoing research continues to explore its cardioprotective roles and potential applications in chronic kidney disease and resistant hypertension.

Pharmacological Actions

Competitive antagonism of mineralocorticoid receptors in renal tubular epithelial cells leading to increased sodium and water excretion while conserving potassium.
Reduction of myocardial and vascular fibrosis by inhibiting aldosterone-mediated pro-fibrotic gene expression, thereby improving cardiac remodeling.
Lowering of blood pressure through natriuretic and diuretic effects without significant loss of potassium, differentiating it from thiazide and loop diuretics.
Reduction in mortality and morbidity in patients with heart failure following acute myocardial infarction by attenuating adverse cardiac remodeling.
Anti-hypertensive effect useful for management of primary and secondary hypertension.
Selective mineralocorticoid receptor blockade with minimal interaction with androgen and progesterone receptors, reducing hormonal side effects.
Modulation of electrolyte balance by decreasing potassium excretion, necessitating monitoring for hyperkalemia.
Improvement in endothelial function due to reduction of aldosterone-induced oxidative stress and inflammation.
Potential attenuation of insulin resistance and beneficial effects on metabolic syndrome parameters suggested by emerging research.
Influence on the renin-angiotensin-aldosterone system (RAAS) with downstream effects on vascular tone and fluid balance.
Favorable safety profile compared with older aldosterone antagonists, with fewer endocrine-related adverse effects.
Demonstrated efficacy in reducing proteinuria in some studies, suggesting renal protective properties.
Potential enhancement of efficacy when combined with other heart failure therapies such as ACE inhibitors and beta-blockers.
Pharmacodynamic effect sustained over 24 hours supporting once or twice daily dosing schedules.
Modulates electrolyte transport without significant changes to serum magnesium.

Therapeutic Or Clinical Uses

Risk reduction of death in patients with heart failure and reduced ejection fraction (≤40%) after acute myocardial infarction.
Treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents.
Management of congestive heart failure by mitigating fluid overload and improving cardiac function.
Potential use in patients with resistant hypertension to normalize blood pressure through potassium-sparing diuretic effects.
Adjunct therapy in chronic heart failure to prevent aldosterone-mediated cardiac remodeling and fibrosis.
Therapy for patients intolerant to spironolactone due to fewer hormonal side effects.
Utilized to prevent hyperaldosteronism-related damage in cardiovascular disease contexts.
Research-supported investigation for renal protection in diabetic nephropathy and chronic kidney disease.
Off-label uses include reducing proteinuria and other cardiovascular risk factors linked to aldosterone excess.
Treatment option in patients with metabolic syndrome who require mineralocorticoid receptor antagonism.
Potential role in reducing hospitalization rates for heart failure exacerbations.
Management of edema where potassium-sparing diuretics are indicated, reducing risk of hypokalemia.
Improvement of endothelial dysfunction contributing to cardiovascular risk reduction.
Therapeutic application in patients requiring modulation of RAAS for blood pressure and fluid status control.
Considered in combination regimens for comprehensive heart failure and hypertension management.

Side Or Adverse Effects

Hyperkalemia, which may present with nausea, muscle weakness, paresthesia, chest pain, and arrhythmias.
Dizziness and light-headedness, especially during initiation or dose escalation due to blood pressure reduction.
Headache, commonly mild to moderate in intensity.
Gastrointestinal disturbances including diarrhea and vomiting in rare cases.
Fatigue and weakness related to electrolyte imbalances.
Orthostatic hypotension leading to increased risk of falls in susceptible populations.
Rare allergic reactions including rash, hives, and angioedema.
Elevations in serum creatinine and blood urea nitrogen reflecting renal function changes.
Electrolyte imbalances beyond potassium, such as hyponatremia in rare cases.
Potential for irregular or rapid heartbeats secondary to electrolyte disturbances.
Swelling or edema of lower extremities, indicative of fluid retention or heart failure worsening.
Potential hormonal effects are minimal compared to spironolactone but still possible.
Rare cases of gynecomastia or breast tenderness have been reported.
Fatigue and weakness due to hyperkalemia or hypotension.
Transient increase in liver enzymes during therapy.

Precautions

Regular monitoring of serum potassium and renal function is essential during therapy to prevent hyperkalemia and nephrotoxicity.
Use caution in patients with pre-existing kidney disease or those receiving concomitant nephrotoxic medications.
Avoid potassium supplements and potassium-containing salt substitutes unless explicitly prescribed by a healthcare provider.
Patients should be monitored closely when initiating therapy or changing doses due to potential electrolyte disturbances.
Caution advised in patients with diabetes mellitus, especially those with microalbuminuria or proteinuria.
Impaired hepatic function may require judicious use and dose adjustments due to altered metabolism.
Pregnant or breastfeeding women should consult healthcare providers; safety has not been fully established.
Concomitant use with drugs affecting CYP3A4 may necessitate dose modifications or avoidance due to increased eplerenone levels.
Patients with hypotension or volume depletion should be stabilized prior to starting therapy to minimize dizziness and syncope.
Use caution when combined with other antihypertensive agents to avoid excessive blood pressure reduction.
Inform patients about signs and symptoms of hyperkalemia and instruct them to seek prompt medical attention if these occur.
Adjust dose or discontinue in cases of acute kidney injury or severe electrolyte abnormalities.
Advise patients to avoid over-the-counter NSAIDs without medical advice as these can impair renal function and exacerbate side effects.
Cautious use is advised in elderly patients due to increased risk of adverse reactions.
Patients should disclose all medications, including herbal supplements, to prevent harmful interactions.

Warnings

Contraindicated in patients with hyperkalemia or baseline elevated serum potassium levels due to risk of life-threatening arrhythmias.
Not to be used in severe renal impairment or kidney failure, as the risk of hyperkalemia is significantly increased.
Use contraindicated in patients with type 2 diabetes mellitus who have elevated urinary albumin levels due to adverse safety profile.
Risk of severe hyperkalemia when used concomitantly with potassium supplements, potassium-sparing diuretics, or strong CYP3A4 inhibitors.
Treatment should be avoided or closely monitored if combined with drugs that reduce renal function or cause electrolyte disturbances.
Potential risk of hypotension and syncope particularly in volume-depleted or elderly patients.
Must be used with caution in patients with liver disease due to altered metabolism and elimination.
Avoid abrupt discontinuation to prevent rebound increases in aldosterone levels and associated adverse cardiovascular events.
Risk of drug-induced kidney injury necessitates regular renal function monitoring.
Contraindicated in patients with known hypersensitivity to eplerenone or any of its components.
Rare but serious allergic reactions can occur and need immediate medical attention.
Potential fertility effects in men; discuss reproductive plans prior to therapy.
The full safety profile during pregnancy is unknown; use only if clearly needed.
Interaction with certain antibiotics and antifungal agents necessitates temporal separation or alternative therapies.
Close medical supervision required during initiation in patients with multiple comorbidities and polypharmacy.

Contraindication

Known hypersensitivity or allergy to eplerenone or any formulation components.
Baseline hyperkalemia (serum potassium >5.0 mEq/L or per lab-specific reference).
Severe renal impairment or patients requiring dialysis.
Type 2 diabetes mellitus patients with elevated urinary albumin excretion (microalbuminuria or macroalbuminuria).
Concurrent use with potassium-sparing diuretics such as amiloride, spironolactone, or triamterene unless under strict medical supervision.
Use with strong CYP3A4 inhibitors, including clarithromycin, telithromycin, itraconazole, ketoconazole, and certain HIV protease inhibitors.
Pregnancy unless potential benefits justify the potential risk to the fetus.
Lactation unless benefits outweigh risks; consider breastfeeding cessation.
Patients with severe liver dysfunction due to altered metabolism.
Concomitant use with potassium supplements or potassium-containing salt substitutes without medical supervision.
Known disorders causing hyperkalemia such as Addison's disease without management.
Patients with hypotension or volume depletion not stabilized prior to initiation.
History of drug-induced hyperkalemia related to mineralocorticoid receptor antagonists.
Pediatric use has not been established; contraindicated due to lack of safety data.
Patients unable to adhere to frequent laboratory monitoring or follow-up.

Drug Interactions

Potassium supplements and potassium-containing salt substitutes increase risk of hyperkalemia.
Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, telithromycin) significantly increase eplerenone plasma levels and risk of toxicity.
Concurrent use with potassium-sparing diuretics (spironolactone, triamterene, amiloride) increases potassium retention, heightening hyperkalemia risk.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and celecoxib may reduce renal function and decrease antihypertensive efficacy.
Certain HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir) can inhibit CYP3A4, increasing eplerenone concentration.
Lithium toxicity risk may be enhanced when used with eplerenone due to altered renal clearance.
Concomitant use with other antihypertensives like ACE inhibitors (enalapril, lisinopril), ARBs (valsartan, olmesartan), and beta-blockers may potentiate hypotensive effects.
Antiarrhythmic agents such as amiodarone and dronedarone can interact to affect cardiac conduction and electrolyte balance.
Diltiazem can inhibit CYP3A4 and increase systemic exposure to eplerenone.
Use with diuretics causing volume depletion may increase hypotension risk during therapy initiation.
Macrolide antibiotics increase the risk of eplerenone accumulation via CYP3A4 inhibition.
Herbal products like St. John’s Wort, a CYP3A4 inducer, may decrease eplerenone effectiveness.
Concomitant use of indomethacin and other NSAIDs increases risk for renal impairment and loss of antihypertensive efficacy.
Monitoring for serum potassium and renal function is recommended when combined with interacting drugs.
Drug interactions may require dose adjustments, increased monitoring, or avoidance depending on severity.

Preparations Of The Drug

Inspra oral tablets, available in 25 mg strength for initiation and titration in heart failure management.
Inspra oral tablets, 50 mg strength used as maintenance dose for hypertension and heart failure.
Tablets formulated for oral administration with favorable bioavailability and stability at room temperature.
Brand availability includes prescription-only medication, with packaging designed for outpatient use.
No injectable or alternate formulations are currently marketed, limiting administration to oral route.
Tablets should be stored away from moisture and heat to maintain potency.
Generic formulations available under the name eplerenone with bioequivalent standards.
Formulations free from lactose and gluten, suitable for patients with common excipient sensitivities.
No combination products marketed; used as monotherapy or part of multi-drug regimens.
Manufactured complying with current Good Manufacturing Practices (cGMP) ensuring quality and purity.
Packaging includes patient-friendly labeling emphasizing dosing instructions and precautions.
Available under prescription in standard blister packs or bottles depending on manufacturer.
Stability data supports shelf life of typically 24 months under recommended storage conditions.
Tablets are scored for ease of splitting when dose adjustments are necessary.
Supplementary patient leaflets provide comprehensive guidance on administration and safety.